Abstract
Objective: To determine the efficacy and tolerability of high dose biotin in persons with progressive MS. Background: High doses of biotin are reported to improve neurologic function in a small percentage of persons with progressive MS. We wished to document these potential benefits in a “real world” MS specialty clinic. Design/Methods: Three groups of patients with clinically definite multiple sclerosis were evaluated, those with relapses well controlled on disease-modifying therapy yet having progressive disability, patients with secondary progressive MS, no longer on disease-modifying therapy, and patients with primary progressive multiple sclerosis. High dose, pharmaceutical grade biotin, in 300 mg capsules, was prepared by a compounding pharmacy, One capsule per day was prescribed. Neurologic exams and blood work monitoring for toxicity were obtained at baseline and at three-month intervals on drug. Brain MRIs were obtained at baseline and after one year on biotin. Results: Twenty one patients were treated, eleven with secondary progressive MS, four with primary progressive MS, and six patients with relapsing remitting MS. Ten patients were on various disease-modifying therapies. There were 10 males and 11 females, ranging in age from 41 to 74 years. EDSS scores ranged from 4 to 6.5. To date, no patient experienced an adverse event. Of patients evaluated at three months, one patient’s EDSS improved from 6.5 to 6.0, with resolution of arthritic pain. One patient noted greatly improved energy with a 10[percnt] improvement in 25-foot timed walk. Data on all patients at nine-month and twelve-month exams will be presented. Conclusion: High dose biotin, administered daily to persons with progressive MS is well tolerated and results in improvement of neurologic function is a subset of such individuals.
Disclosure: Dr. Birnbaum received research support from Biogen-Idec and Hoffman-LaRoche. Dr. Stulc has nothing to disclose. Dr. Snyder has nothing to disclose.
Monday, April 18 2016, 8:30 am-7:00 pm
- Copyright © 2016 by AAN Enterprises, Inc.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
